STX.L
Shield Therapeutics plc [STX.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
STX.L Stock Summary
Top 10 Correlated ETFs
STX.L
Top 10 Correlated Stocks
STX.L
In the News
STX.L Financial details
Company Rating
-
Market Cap
11.93M
Income
-50.67M
Revenue
7.98M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
27
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-0.43
Forward P/E
-
PEG
-0.04
P/S
12.92
P/B
3.24
P/C
-
P/FCF
-2.87
Quick Ratio
0.27
Current Ratio
0.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.19
EPS next Y
-
EPS next Q
-
EPS this Y
84.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
62.51%
Revenue last 5Y
-17.77%
Revenue Q/Q
44.27%
EPS Q/Q
-87.92%
-
-
-
-
SMA20
-20.4%
SMA50
-34.07%
SMA100
-16.78%
Inst Own
-
Inst Trans
-
ROA
-183%
ROE
-174%
ROC
-2.25%
Gross Margin
45%
Oper. Margin
-575%
Profit Margin
-905%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.5-12.85
52W High
-80.42%
52W Low
+135%
RSI
35.71
Rel Volume
-
Avg Volume
5.96M
Volume
14.23K
Perf Week
0%
Perf Month
-22.95%
Perf Quarter
-14.55%
Perf Half Y
-38.16%
-
-
-
-
Beta
0.844
-
-
Volatility
0.04%, 0.27%
Prev Close
0%
Price
2.35
Change
6.82%
Company Profile
- Volume Average 5.96M
- Market Capitalization 11.93M
- Employee 27
- CEO Mr. Gregory P. Madison
- Headquarters Gateshead,GB
- IPO Date 2016-02-26
-
Website
https://www.shieldtherapeutics.com 
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
